Abstract. Growth (3, 7) and also an increased mortality (8) of such patients. Recently, two controlled studies of GH replacement therapy for 4-6 months in GH -deficient adults reported beneficial effects on fea¬ tures such as body composition, muscle strength, exercise capacity, and psychological well-being, all of which were abnormal during placebo treatment (9-11).
age 26. 4 (1.7) years), who had completed 4 months of GH therapy in a double-blind placebo-controlled cross-over study were followed, for further 16.1 (0.8) months of uninterrupted GH therapy in an open design. A significant mean increase of 1.3 cm in linear height was recorded, whereas body mass index remained unchanged. Mean muscle volume of the thigh, estimated by computerised tomography, increased significantly compared with that of the initial placebo period (p=0.01), and a slight decrease was recorded in adipose tissue volume of the thigh (p=0.10) and subscapular skinfold thickness (p=0.10). Still, the muscle to fat ratio of the thigh was significantly lower compared with that of normal subjects (72.6/27.4 vs 77.9/22.1) (p<0.01). The mean isometric strength of the quadriceps muscles increased significantly during long-term GH therapy (p<0.01), but remained lower compared with that of normal subjects (1.66 (0.10) vs 2.13 (0.11) Nm/kg body weight). Exercise capacity performed on a bicycle ergometer increased significantly after long-term therapy (p<0.05), but still did not reach the values seen in normal subjects (22.5 (3.4) vs 37. 4 (4.2) watt \m=.\min \m=.\ kg\ m=-\ 1\ m=. \ No adverse reactions were recorded during long-term therapy and hemoglobin A1c remained unchanged. These data suggest that long-term GH replacement therapy in GH-deficient adults has beneficial effects on several physiological features which are subnormal in these patients.
The primary goal of growth hormone therapy has been to increase linear height in GH-deficient children. The criterion for termination of therapy varies from attainment of a certain target height (1) (2) (3) to complete cessation of longitudinal growth or fusion of epiphyses (3) (4) (5) . Neither of these cri¬ teria is in accordance with normal physiology, since GH secretion continues in adulthood although at a declining rate (6 (3, 7) and also an increased mortality (8) of such patients. Recently, two controlled studies of GH replacement therapy for 4-6 months in GH -deficient adults reported beneficial effects on fea¬ tures such as body composition, muscle strength, exercise capacity, and psychological well-being, all of which were abnormal during placebo treatment (9) (10) (11) .
In order to examine more long-term effects of GH therapy in GH-deficient adults we continued a double-blind protocol (9) as an open study of 16 months of uninterrupted GH therapy.
Patients and Methods
The GH-deficient patients in the present study had all participated in a double-blind placebo-controlled cross¬ over study on the effects of 4 months GH therapy (9 (9) .
For comparison, all of the above described measure¬ ments except HbAlc were also performed in healthy, un¬ treated subjects. Twenty-one healthy subjects underwent measurements of conventional anthropometries, serum IGF-I, and muscle strength, and 13 of these subjects also had a CT scan of their thighs ( A small but significant increase in linear height of the patients was recorded at the end of the study period, whereas body weight only increased insig¬ nificantly (Table 1) . Body mass index (BMI) re¬ mained unchanged and did not differ from that of the control group (N=21). Mean muscle volume of both thighs increased during long-term GH ther¬ apy (p<0.01) and was significantly higher com¬ pared with that during the placebo period (p<0.01), whereas the increase compared with that during the short-term GH period did not quite reach significance (Fig. 1) . The decrease in adipose tissue volume of the thighs and subscapular skin¬ fold thickness after long-term GH therapy was not statistically significant compared with any previous measurements (Fig. 1) . The muscle to fat ratio of the thighs increased significantly during long-term GH therapy compared with both values in the cross-over study, but the ratio still remained signifi¬ cantly lower than that of the control group (p<0.01) ( Table 1) .
The mean isometric muscle strength of the right and left quadriceps, which did not change during the cross-over study, increased significantly during long-term GH therapy (p<0.01). Fig. 2 (Fig. 2) . Exercise capacity also increased significantly following long-term GH therapy with both values in the cross-over study (p<0.05). When corrected for body weight, exercise capacity was significantly lower in all the patients compared with the control group (p<0.01) (Fig. 2 ). In the cross-over study heart rate, both at rest and during exercise, was higher following GH therapy than during the placebo period, whereas during long-term GH therapy, the levels were in¬ termediate to the two previous measurements (data not shown). 
Discussion
This study is the first to report results of long-term GH therapy in GH-deficient adults. A significant increase in muscle to fat ratio, isometric muscle strength, and exercise capacity was recorded when compared with previous measurements in the same patients during both short-term GH and placebo therapy. These achievements represented only a partial normalization when compared with an un¬ treated group of healthy subjects.
It would have strengthened the long-term study had it included a placebo-treated patient group, but that was not feasible. It is, however, very un¬ likely that the observed effects reflected natural changes with time, since both lean body mass, max¬ imal isometric strength and exercise capacity de¬ cline with age already from the onset of early adult¬ hood (12) (13) (14) . It (11, 15) . The present long-term data support and extend these findings. The adverse reactions reported so far consist of moderate fluid retention (9, 10) , which is dose-dependent and in most cases transient as supported by the fact that such complaints were not reported in this longterm study. Theoretically, impairment of glucose tolerance could be suspected on the basis of the well-known insulin antagonistic actions of GH (17) . HbAlc however, remained unchanged in the present study.
Surveys in adults with untreated GH deficiency point at various degrees of psycho-social maladjust¬ ments (3, 7) . A recent epidemiological study re¬ ported significantly increased overall mortality of hypopituitary patients, which could be ascribed to premature cardiovascular deaths (myocardial in¬ farction and cardiac failure), in spite of adequate replacement therapy with thyroxine, sex steroids and corticosteroids (8) . The (10) , since high levels of these features are associated with increased cardiovascular mor¬ bidity (18) . Furthermore, GH administration has been reported to increase myocardial contractility in both normal subjects and GH-deficient adults (9, 19, 20) . On the other hand, GH excess (21) and hyperinsulinemia (22) have also been associated with increased cardiovascular morbidity in epide¬ miological studies, indicating that long-term GH should be used with caution and probably only at replacement doses.
At any rate, the data by Rosen & Bengtsson (8) clearly imply that current treatment of adult hypopituitarism needs to be improved.
In conclusion, the present results indicate that GH replacement therapy in GH-deficient adults offer significant benefits, also when given for a rela¬ tively long time, without significant adverse reac¬ tions. Therefore, GH treatment should be consid¬ ered in these patients, at least for some years or decades after cessation of linear growth.
